- Monovalent
- Multivalent
Pediatric Vaccine Market size was valued at USD 23,749.8 million in 2023 and is expected to grow at a CAGR of 9.8% over the forecast year to reach USD 45,695.8 million in 2030. Vaccines for children are administered to guard against serious and frequently fatal infections. It primes the body to combat the illness more quickly and successfully by boosting the body. Globally increasing awareness of vaccinations and immunization initiatives will propel the pediatric vaccine industry.
Moreover, opportunities are surfacing in vaccine technology, including mRNA vaccines, and also through the increasing requirements for combination vaccines to reduce the number of injections required. Significant restrictions to the pediatric vaccine market include the presence of vaccine hesitation, where parents and caregivers refuse to vaccinate their children because of safety concerns or unsubstantiated myths. Furthermore, coverage in low-income or rural regions is at a disadvantage as the availability of healthcare infrastructure differs across different areas. The cost of developing and manufacturing vaccines may also become a formidable challenge, particularly for smaller manufacturers.
This being the third reason why the vaccination rate of children is suboptimal, it's because of the regulatory hurdles and the long time taken to have approval for a new vaccine. Thus, these elements have contributed to the challenges of achieving high vaccination rates among children. These are the trends that emerging in the market by a phenomenon where the public and private sectors have been joining forces to increase vaccination coverage. Reports recently indicate that the global market for pediatric vaccines will be about $40 billion in 2027 with a CAGR of around 7% in comparison, showing a continuation of the efforts to advance child health through immunization.
Study Period
2024-2030Base Year
2023CAGR
9.8%Largest Market
North AmericaFastest Growing Market
Asia Pacific
The pediatric vaccine market is steadily growing with various opportunities it includes inventing mRNA vaccines and developing new vaccine technology to open avenues for more effective immunization against a wide series of diseases. For instance, with a global CAGR of almost 8% during 2023-2028 where parents opt for fewer injections in children, the combination vaccines market can be expanded. Additionally, public health campaigns increase awareness of the importance of vaccinations. Therefore, the demand for pediatric vaccines increases. It's also reported that immunization programs are expanding globally, especially in developing countries, because global health organizations are providing support to enhance vaccine accessibility and coverage. Overall, pediatric vaccines have a promising future in growth as healthcare systems continue to improve the health of children through new inventions and global efforts toward immunization.
By Vaccine
By Indication
By Technology
The pediatric vaccine market was valued at USD 23,749.8 million in 2023 and is expected to grow at a CAGR of 9.8% over the forecast year to reach USD 45,695.8 million in 2030.
The pediatric vaccine market is growing due to increased awareness of vaccines and their immunization programs across the globe.
The pediatric vaccine market is emerging with this trend it includes public and private sectors have been joining forces to increase vaccination coverage.
North America is the dominant region in the pediatric vaccine market.
Asai-Pacific is the fastest-growing region in the pediatric vaccine market.
1.Executive Summary |
2.Global Pediatric Vaccine Market Introduction |
2.1.Global Pediatric Vaccine Market - Taxonomy |
2.2.Global Pediatric Vaccine Market - Definitions |
2.2.1.Vaccine |
2.2.2.Indication |
2.2.3.Technology |
2.2.4.Region |
3.Global Pediatric Vaccine Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Pediatric Vaccine Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Pediatric Vaccine Market By Vaccine, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Monovalent |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Multivalent |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
6.Global Pediatric Vaccine Market By Indication, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Pneumococcal Conjugate Vaccine |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. DTP Vaccine |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Influenza |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Meningococcal Vaccine |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Polio Vaccine |
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
6.6. Rotavirus Vaccine |
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.6.3. Market Opportunity Analysis |
6.7. MMR Vaccine |
6.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.7.3. Market Opportunity Analysis |
6.8. Varicella Virus Vaccine |
6.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.8.3. Market Opportunity Analysis |
7.Global Pediatric Vaccine Market By Technology, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Live or Attenuated Vaccine |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Inactivated or Killed Vaccine |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Toxoid Vaccine |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Conjugate Vaccine |
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Subunit Vaccine |
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
7.6. Recombinant Vector Vaccine |
7.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.6.3. Market Opportunity Analysis |
8.Global Pediatric Vaccine Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Pediatric Vaccine Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Vaccine Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Monovalent |
9.1.2.Multivalent |
9.2. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Pneumococcal Conjugate Vaccine |
9.2.2.DTP Vaccine |
9.2.3.Influenza |
9.2.4.Meningococcal Vaccine |
9.2.5.Polio Vaccine |
9.2.6.Rotavirus Vaccine |
9.2.7.MMR Vaccine |
9.2.8.Varicella Virus Vaccine |
9.3. Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Live or Attenuated Vaccine |
9.3.2.Inactivated or Killed Vaccine |
9.3.3.Toxoid Vaccine |
9.3.4.Conjugate Vaccine |
9.3.5.Subunit Vaccine |
9.3.6.Recombinant Vector Vaccine |
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Pediatric Vaccine Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Vaccine Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Monovalent |
10.1.2.Multivalent |
10.2. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Pneumococcal Conjugate Vaccine |
10.2.2.DTP Vaccine |
10.2.3.Influenza |
10.2.4.Meningococcal Vaccine |
10.2.5.Polio Vaccine |
10.2.6.Rotavirus Vaccine |
10.2.7.MMR Vaccine |
10.2.8.Varicella Virus Vaccine |
10.3. Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Live or Attenuated Vaccine |
10.3.2.Inactivated or Killed Vaccine |
10.3.3.Toxoid Vaccine |
10.3.4.Conjugate Vaccine |
10.3.5.Subunit Vaccine |
10.3.6.Recombinant Vector Vaccine |
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) Pediatric Vaccine Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Vaccine Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Monovalent |
11.1.2.Multivalent |
11.2. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Pneumococcal Conjugate Vaccine |
11.2.2.DTP Vaccine |
11.2.3.Influenza |
11.2.4.Meningococcal Vaccine |
11.2.5.Polio Vaccine |
11.2.6.Rotavirus Vaccine |
11.2.7.MMR Vaccine |
11.2.8.Varicella Virus Vaccine |
11.3. Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Live or Attenuated Vaccine |
11.3.2.Inactivated or Killed Vaccine |
11.3.3.Toxoid Vaccine |
11.3.4.Conjugate Vaccine |
11.3.5.Subunit Vaccine |
11.3.6.Recombinant Vector Vaccine |
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Pediatric Vaccine Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Vaccine Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Monovalent |
12.1.2.Multivalent |
12.2. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Pneumococcal Conjugate Vaccine |
12.2.2.DTP Vaccine |
12.2.3.Influenza |
12.2.4.Meningococcal Vaccine |
12.2.5.Polio Vaccine |
12.2.6.Rotavirus Vaccine |
12.2.7.MMR Vaccine |
12.2.8.Varicella Virus Vaccine |
12.3. Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Live or Attenuated Vaccine |
12.3.2.Inactivated or Killed Vaccine |
12.3.3.Toxoid Vaccine |
12.3.4.Conjugate Vaccine |
12.3.5.Subunit Vaccine |
12.3.6.Recombinant Vector Vaccine |
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Pediatric Vaccine Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Vaccine Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Monovalent |
13.1.2.Multivalent |
13.2. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Pneumococcal Conjugate Vaccine |
13.2.2.DTP Vaccine |
13.2.3.Influenza |
13.2.4.Meningococcal Vaccine |
13.2.5.Polio Vaccine |
13.2.6.Rotavirus Vaccine |
13.2.7.MMR Vaccine |
13.2.8.Varicella Virus Vaccine |
13.3. Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Live or Attenuated Vaccine |
13.3.2.Inactivated or Killed Vaccine |
13.3.3.Toxoid Vaccine |
13.3.4.Conjugate Vaccine |
13.3.5.Subunit Vaccine |
13.3.6.Recombinant Vector Vaccine |
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Sanofi |
14.2.2.AstraZeneca |
14.2.3.GSK plc |
14.2.4.Pfizer, Inc. |
14.2.5.Zydus Group |
14.2.6.Serum Institute of India Pvt. Ltd. |
14.2.7.Indian Immunologicals Ltd. |
14.2.8.SINOVAC |
14.2.9.Panacea Biotec |
14.2.10.BIO-MED |
15. Research Methodology |
16. Appendix and Abbreviations |